Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.47 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 4/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637435 | 0.88 | NPY1R (0.58) | SRCAPPNPY1RRAMP1CALCRL | |
| SCHEMBL5638695 | 0.86 | KDM4E (0.53) | SRCAPPNPY1RRAMP1CALCRL | |
| SCHEMBL5637803 | 0.85 | SRC (0.52) | SRCAPPNPY1RRAMP1CALCRL | |
| SCHEMBL7950295 | 0.84 | SRC (0.67) | SRCAPPNPY1R | |
| SCHEMBL14171421 | 0.83 | FNTA (0.43) | SRCAPPNPY1RRAMP1CALCRL | |
| SCHEMBL5640916 | 0.82 | SRC (0.58) | SRCAPPNPY1R | |
| SCHEMBL5637302 | 0.81 | FNTA (0.42) | SRCAPPNPY1RRAMP1CALCRL | |
| SCHEMBL5637296 | 0.81 | FNTA (0.44) | SRCAPPNPY1RRAMP1CALCRL | |
| SCHEMBL5638319 | 0.80 | L3MBTL1 (0.47) | SRCAPPNPY1RRAMP1CALCRL | |
| SCHEMBL5639237 | 0.78 | NPY1R (0.50) | SRCAPPNPY1RRAMP1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1549600-A1 | KETONES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004011410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | SRC 1866/4885APP 3071/4885NPY1R 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.